Abstract
BACKGROUND: The standard of care for HCV Hepatitis is the combination of interferon (IFN) plus Ribavirin. In HIV patients the use of this combination therapy may induce drug interactions, and reduces the adherence to HAART.The aim of this study is to evaluate safety and efficacy of a 48 weeks daily dose IFN schedule. METHODS: We evaluated 50 coinfected patients; alpha IFN 2a was administered at a dose of 3 MU daily. The baseline values were the following : CD4+ 515 cells/mmc (mean); HIV-RNA
Original language | English |
---|---|
Pages (from-to) | 17 |
Number of pages | 1 |
Journal | BMC Infectious Diseases |
Volume | 2 |
Issue number | 1 |
Publication status | Published - Aug 28 2002 |
ASJC Scopus subject areas
- Infectious Diseases